Product Images Sildenafil

This appears to be a medication label for Sildenafil Tablets, USP with an NDC code of 82647-212-14. The label indicates that there are 1000 tablets and that it is prescription-only medicine. The rest of the text is not legible due to errors.*

Sildenafil Tablets, USP is a prescription medicine available in the form of tablets and can only be obtained through a valid prescription. The NDC number for this product is 82647-212-30. The other text in the given is illegible and therefore not useful.*

This seems to be a package label for Sildenafil Tablets with important information such as the drug name, dosage (30 tablets), prescription requirements, and NDC number for identification. The rest of the text contains illegible characters and cannot be understood.*

This is a description of a medicine called Sildenafil that comes in 30 tablets and requires a prescription, as indicated by the phrase "Rx Only" at the end and the NDC code. The rest of the text is not related or coherent, most likely due to errors.*

The text describes a study on the effect of Sildenafil and Placebo on the maintenance of erection by baseline score. The study aims to evaluate the effectiveness of Sildenafil in maintaining erections. Figure 6 displays the results of the study.*

Table 2 shows the adverse reactions reported by more than 2% of patients treated with Sildenafil in flexible-dose phase II/III studies. These reactions were more frequent than those reported with the placebo. The adverse reactions reported include headache, flushing, dyspepsia, nasal congestion, abnormal vision, back pain, dizziness, and rash. Abnormal vision was predominantly mild and transient, with a color tinge to vision, and only one patient discontinued the treatment due to abnormal vision.*

The table presents hemodynamic data in patients with stable ischemic heart disease before and after the intravenous administration of 40 mg of Sildenafil. The data includes mean values and standard deviation for PAOP, PAP, RAP, SAP, diastolic SAP, cardiac output, and heart rate. The data is presented before and 4 minutes after exercise, with the patients being divided into two groups, one receiving Sildenafil and one not.*

Table 1 shows the adverse reactions reported by patients treated with sildenafil in fixed-dose Phase I/III studies. The table includes the percentage of patients experiencing adverse reactions, categorized by dosage. Adverse reactions that were reported by more than 2% of patients and were more frequent than placebo are presented. The adverse reactions listed include headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness, and rash. Abnormal vision was described as mild to moderate in severity and transient, with a predominantly color tinge to vision, but also increased sensitivity to light or blurred vision.*